Mutations in IDH1 lead to neomorphic IDH activity that converts αKG into the oncometabolite D-2 hydroxyglutarate (D-2HG), which suppresses the homologous recombination repair system and decreases intracellular reducing power (NADPH), resulting in improved cellular sensitivity to multimodal therapies and tumor progression. Here, IDH1 is linked to neoplasm.